Skip to Content
COVID-19 Resources
Cancer Diagnosis Program
Contact NExT
Show menu
Search this site
Last Updated: 08/16/21

Current Funding Opportunities

The Requests for Applications (RFAs) and Program Announcements (PAs) listed below communicate CDP’s current funding opportunities and research interests. CDP staff contacts and published notices are provided in the summary link for each opportunity. We encourage you to discuss your proposed research with a CDP program director before you submit an application. This page updates to reflect the active Funding Opportunities.

To receive email updates, click here or follow us on Twitter.

National Cancer Institute’s Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required): PAR-21-033

Reissue of PAR-18-560
Posted date: November 10, 2020
Expiration date: January 8, 2024
Application Receipt Dates: Standard application dates apply for non-AIDS applications; standard AIDS dates apply for AIDS applications.

The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute’s (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research; therefore, applications that propose phase III clinical trials will be deemed non-responsive and will not be reviewed.

See full announcement here.

Contact: Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional): PAR-20-292

Reissue of PAR-19-356
Posted date: August 24, 2020
Expiration date: July 21, 2022
Application Receipt Dates: Standard application dates apply for non-AIDS applications; standard AIDS dates apply for AIDS applications.

This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well.

This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed.

See full announcement here.

Contact: Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

Assay Validation of High-Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed): PAR-20-313

Reissue of PAR-18-317. Posted date: October 13, 2020;
Expiration date: October 11, 2023.
Application receipt dates: February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

See full announcement here.

Contact: Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

Assay Validation for High Quality Markers for Clinical Studies in Cancer (UH3) (Clinical Trials Not Allowed): PAR-20-314

Reissue of PAR-18-310, Posted date: October 13, 2020;
Expiration Date: October 11, 2023
Application receipt dates: February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

See full announcement here.

Contact Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed): PAR-20-074.

Reissue of PAR-17-003; Posted date: December 10, 2019.
Expiration Date: October 29, 2022.
Application Due dates: February 28, 2020; July 10, 2020; October 27, 2020; February 26, 2021; July 13, 2021; October 26, 2021; February 28, 2022; July 11, 2022; October 28, 2022, by 5 pm local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this FOA should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

See full announcement here.

Contact Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 — Clinical Trial Optional): PAR-21-166

Re-issue of PAR-18-530
Posted date: March 25, 2021
Expiration date: January 08, 2024
Application receipt dates: NIH standard due dates apply

This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status.

See full announcement here.

Bioengineering Technologies

The NIH bioengineering program supports basic, applied, and translational bioengineering research that addresses important biological or medical research problems.

CDP contact: Mr. Miguel Ossandon: 240-276-5714, ossandom@mail.nih.gov

Exploratory/Developmental Bioengineering Research Grants [EBRG]: PAR-19-149 and PAR-19-150 (R21)

Reissue of PA-18-286
Release/Posted Date: January 8, 2019
Expiration date: January 8, 2022
Application Receipt Dates: standard receipt dates for non-AIDS applications; standard AIDS dates for AIDS applications

The EBRGs support early bioengineering research. EBRG applications may contain minimal or no preliminary data, and may propose hypothesis-driven, discovery-driven or design-directed research.

See full announcements here and here.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Bioengineering Research Grants [BRG]: PAR-19-158 and PAR-19-159 (R01)

Reissue of PAR-18-206
Posted Date: January 8, 2019;
Expiration date: January 8, 2022
Application Receipt Dates: Standard receipt dates for non-AIDS applications; standard AIDS dates for AIDS applications.

The purpose of this FOA is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach.

See full announcements here and here.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Bioengineering Research Partnerships [BRP]: PAR-19-156 and PAR-19-157 (U01)

Reissue of PAR-18-208
Release/Posted Date: January 8, 2019;
Expiration date: January 8, 2022
Application Receipt Dates: standard receipt dates for non-AIDS applications; standard AIDS dates for AIDS applications

The BRPs support large basic, applied, and translational multi-disciplinary research performed by multiple organizations that applies an integrative approach, which includes bioengineering and biomedical/clinical components.

See full announcements here and here.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Small Business Innovation Research Funding Opportunities

NIH/NCI 438 - Understanding Cancer Tumor Genomic Results: Technology Applications for Community Providers

Receipt date: October 28, 2021 5:00 PM Eastern Daylight Time

The goal is to design and develop products such as tools, technologies, and/or services to: (i) inform oncology providers about tumor/somatic testing and current NCCN guidelines, (ii) help oncology providers evaluate the need for tumor/somatic testing for specific cancer patients, (iii) assist oncology providers with interpretation of tumor/somatic test results, including the impact of incidental germline findings, and (iv) help oncology providers communicate NGS results to their patients. Interpretation of NGS results must be personalized for individual patients. Products that cater to settings with limited or no access to genetic counselors, or on-site tumor boards, are encouraged. Products should: (i) identify strategies for enhancing provider understanding of cancer genomic test results; (ii) assist with provider communication of test results in a clear and lay-friendly manner, to aid both treatment and life planning decisions; (iii) inform providers about genetic counseling and clinical trial resources for their patients; (iv) offer remote technology applications such as video and telephone guidance; and (v) incorporate perspectives of populations experiencing disparities in cancer outcomes, such as minority and rural communities. In addition, contractors must evaluate, pilot and disseminate the product. For more information, click here.

Contact: Cherie Wells (ncioasbir@mail.nih.gov)

NIH/NCI 445 - Advanced Manufacturing to Speed Availability of Emerging Autologous Cell-based Therapies

Receipt date: October 28, 2021, 5:00 p.m. Eastern Daylight Time

The overall goal of this solicitation is to stimulate the development of advanced manufacturing technologies that substantially improve the speed and cost of producing autologous cell-based therapies. Technical solutions are expected to address a key bottleneck in the current manufacturing process for individual cell-based therapies. Ideal solutions will involve parallel processing, rapid release testing, or point of care technology development, although other approaches may also be considered responsive. New technologies must produce cell-based products of equal or superior quality as compared to current manufacturing methods. The development of scalable systems capable of changing the number of cell products produced simultaneously, is strongly encouraged. For example, technologies may involve a modular engineering approach in which the system can be readily adapted as the demand for autologous cell therapies changes.

To achieve the goals of the solicitation, offerors must be improving upon an existing end to end process that they have experience with, rather than developing end to end processes as part of the project. To be responsive, proposals must involve a collaboration between technology developers and clinical researchers with experience developing and treating patients with autologous cell-based cancer therapies. Projects also including an immunologist on the team will be prioritized. Phase I projects will be expected to involve feasibility testing of the proposed advanced manufacturing technology. A key activity during the Phase I project is to benchmark the novel advanced manufacturing approach against the current manufacturing method for a specific autologous cell-based product. More specifically, the research plan must include validating the proposed novel manufacturing approach against a process that has been used to produce product for clinical trials by demonstrating comparability of products with respect to specific critical quality attributes. Phase II projects will be expected to conduct full-scale processing to demonstrate a substantial increase in the speed and cost of producing autologous cell-based therapies. It is anticipated that most offerors will propose to study T-cell-based immunotherapy products, although other cell types are also encouraged (e.g., NK cells). Advanced manufacturing approaches may involve genetic engineering and optimization as appropriate for the cell-based therapy product, but the primary goal is to achieve substantial cost and throughput improvements for the overall vein-to-vein process. For more information, click here.

Cherie Wells (ncioasbir@mail.nih.gov)

NIH/NCI 439 - Advanced Sample Processing Platforms for Downstream Single-cell Multi-omic Analysis

Receipt date: October 28, 2021, 5:00 p.m. Eastern Daylight Time

The offerors are encouraged to integrate the preanalytical workflow from tumor cell dissociation/isolation, enrichment, tracking, cell lysis, to biomolecular isolation on a single platform to enable single cell multimodal-omic analysis. This approach should provide smoother transitions between functional components thereby leading to shorter analysis time and thus higher throughput. In addition, by omitting human intervention, workflow with higher degree of automation should ultimately translate into greater experimental reproducibility. Novel micropillar-based microfluidic platforms that are capable of providing high efficiency separation, isolation and enrichment of single cells and molecules instead of relying on a single-compartment design (e.g. droplet microfluidics, microwell technologies, valved and chambered microchannels, tube-based kits, etc.) for cell and biomolecular processing may be explored. Micropillar arrays within microfluidic channels may serve to physically size-separate genomic DNA from proteins and RNA during cell lysis in a manner compatible with the downstream target analysis.

Overall, at the end of the contract an offeror is expected to provide a robust sample processing platform that easily integrates with scMulti-omic analysis and allow better understanding of heterogeneity in solid tumors and the microenvironment, and also that enable analysis of rare and low-abundant cells such as circulating tumor cells and antigen presenting cells, to potentially open the door to new biomarker and therapeutic targets discoveries in cancer.

The activities that fall within the scope of this solicitation include development of technologies to improve single-cell multi-omic preanalytical microfluidic platforms that integrate steps of the preanalytical workflow such as sample processing, single-cell separation or isolation and enrichment, technologies for solid tumor dissociation/isolation, enrichment and tracking of cancer cells and/or biomolecules for scMulti-omics. Technology proposals focused on developing new or improved molecular analysis will be considered non-responsive to this contract topic. For more information, click here.

Contact: Cherie Wells (ncioasbir@mail.nih.gov)

Informatics Technology for Cancer Research (ITCR) Program (http://itcr.nci.nih.gov/)

ITCR supports a wide range of informatics tools to serve current and emerging needs across the cancer research continuum.

Algorithm Development: PAR-15-334 (R21):

Expired: Pending Reissuance

This FOA supports the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum.

CDP contact: Dr. Aniruddha Ganguly, gangulya@mail.nih.gov

Prototyping and Hardening: PAR-15-332 (U01):

Expired: Pending Reissuance

This FOA supports the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge in support of cancer research.

CDP contact: Dr. Aniruddha Ganguly, gangulya@mail.nih.gov

Enhancement and Dissemination: PAR-15-331 (U24):

Expired: Pending Reissuance

This FOA supports the advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge in support of cancer research.

Sustainment: PAR-15-333 (U24):

Expired: Pending Reissuance

This FOA supports the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum.

CDP contact: Dr. Aniruddha Ganguly, gangulya@mail.nih.gov

FOR THE LATEST INFORMATION ABOUT NCI INITIATIVES, VISIT
Division of Extramural Activities, National Cancer Institute
http://deainfo.nci.nih.gov/funding.htm

National Institutes of Health
U.S. Department of Health and Human Services